Aldosterone excess or escape: Treating resistant hypertension
| Autor: | Leoni Adriana de Souza, Juan Carlos Yugar-Toledo, Cristina Sierra, Otávio Rizzi Coelho, Eduardo Pimenta, Silvia Elaine Ferreira-Melo, Samira Ubaid-Girioli, Antonio Coca, Heitor Moreno, Luiz Cláudio Martins |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Potassium Drug Resistance chemistry.chemical_element Vasodilation Angiotensin-Converting Enzyme Inhibitors Blood Pressure Spironolactone Left ventricular hypertrophy Plasma renin activity Renin-Angiotensin System chemistry.chemical_compound Primary aldosteronism Internal medicine Renin Internal Medicine medicine Humans Aldosterone Mineralocorticoid Receptor Antagonists business.industry Sodium medicine.disease Original Papers Endocrinology Blood pressure chemistry Hypertension Hypertrophy Left Ventricular Endothelium Vascular Cardiology and Cardiovascular Medicine business Angiotensin II Type 1 Receptor Blockers |
| Zdroj: | J Clin Hypertens (Greenwich) |
| ISSN: | 1751-7176 |
| Popis: | Aldosterone excess or “escape” can occur after treatment with medications that block the renin‐angiotensin‐aldosterone system or in undiagnosed primary aldosteronism. Spironolactone is thought to be an important addition to resistant hypertension (RH) treatment. In this study, resistant (RH) and controlled (CH) hypertensives and normotensive patients were submitted to echocardiography, flow‐mediated vasodilation, carotid intima‐media wall thickness studies, renin plasma activity, and aldosterone plasma levels and plasma and urinary sodium and potassium concentrations at baseline (pre‐spironolactone phase). Subsequently, for only RH and CH groups, 25 mg/d spironolactone was added to preexisting treatments over 6 months. Afterwards, these parameters were reassessed (post‐spironolactone phase). The RH and CH groups achieved reductions in blood pressure (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|